Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2008

View Archived Issues

Lilly and TransPharma enter licensing agreement for ViaDerm-hPTH for osteoporosis

Vical receives funding from AnGes for phase III trial of Allovectin-7

Invitrogen acquires Applied Biosystems from Applera

Z-360 safe when combined with gemcitabine in pancreatic cancer patients

Phase I studies characterize MK-0646 in solid tumor patients

Novel compounds for inflammatory disorders claimed in recent patents

Nastech changes name to MDRNA

Dimethyl fumarate shows dual neuroprotective and antiinflammatory effects in multiple sclerosis

Pfizer patents novel sulopenem prodrugs

Novel antidiabetic agents disclosed in recent patent literature

Positive clinical results from studies on JAK2 inhibitor INCB-018424 reported

Victory Pharma's MGX-006 enters first of two clinical studies for pivotal development program

Pfizer completes acquisition of Encysive Pharmaceuticals

The FDA approves Lilly's Cymbalta for fibromyalgia

Transdel and Cato collaborate on phase III Ketotrandel program

Positive phase II results reported for once-daily Arikace in cystic fibrosis

Preclinical profile of novel antidiabetic compound P-1736-05 reported

Lipoxen receives grant from IAVI to research improved HIV vaccine delivery using ImuXen

DSM and Crucell achieve new record in production of IgG antibodies using PER.C6

Opko Health acquires exclusive worldwide rights to Redox's Doxovir for viral conjunctivitis

LLS and Aegera to initiate phase I/II trial of targeted blood cancer therapy AEG-35156

GSK and Mpex enter alliance to develop EPI drug candidates for bacterial infections

Enrollment completed for phase II clinical trial of TRO-19622 in diabetic neuropathy

Acadia's ACP-104 for schizophrenia does not meet endpoints in phase IIb trial

NanoViricides HivCide-I improves survival time in animal HIV study

Allergan receives FDA approval for Trivaris for ophthalmic indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...